Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
10 hedge funds and large institutions have $1.06M invested in Vyant Bio, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
16% less capital invested
Capital invested by funds: $1.26M → $1.06M (-$197K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$146K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$85.9K |
| 3 |
VF
Virtu Financial
New York
|
+$59.6K |
| 4 |
CCT
Country Club Trust
Kansas City,
Missouri
|
+$59.1K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$184K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$103 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $673K | +$146K | +9,880 | +26% |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| $130K | +$85.9K | +5,813 | +161% |
|
3
BlackRock
New York
| $102K | – | – | – |
|
|
CCT
4
Country Club Trust
Kansas City,
Missouri
| $56K | +$59.1K | +4,000 | New |
|
|
VF
5
Virtu Financial
New York
| $56K | +$59.6K | +4,033 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $47K | +$19.4K | +1,310 | +62% |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $1K | -$103 | -7 | -8% |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$2K | -112 | Closed |
|
|
MC
9
Mayo Clinic
Rochester,
Minnesota
| – | -$184K | -89 | Closed |
|
10
Wells Fargo
San Francisco,
California
| – | +$30 | +2 | +67% |
|
VYNT Hedge Fund Activity: Q4 2020 in Review
10 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2020, worth a combined $1.06M — down 16% from $1.26M a quarter earlier.
Fund positioning in VYNT was balanced in Q4 2020: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $146K. The largest seller was Mayo Clinic, exiting entirely with an estimated $184K sold.
- 10 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $1.06M of Vyant Bio, Inc. Common Stock stock for Q4 2020, down 16% quarter-over-quarter.
- 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2020 and 2 closed out, a net change of 0 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2020 was Renaissance Technologies, an estimated $146K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2020 was Mayo Clinic, an estimated $184K sold.
Based on aggregated 13F filings for Q4 2020.